Merck and Moderna's mRNA vaccine intismeran autogene slowed the return and spread of melanoma when added to an existing treatment in a late-stage trial. One trial cannot say which other cancers the same approach can treat.
Reality
- Evidence35
- Adoption
- Insufficient
- Hype gap+10
- Incentives40
- Confidence40
Intismeran autogene plus Keytruda beat Keytruda alone in resected melanoma. The market added roughly $35bn to Moderna on a result the companies described only in adjectives.
Perspective Coverage
6 publishers
- Builder
- Builder 29%
- Operator
- Operator 25%
- Investor
- Investor 46%
Reality
- Evidence45
- Adoption5
- Hype gap+55
- Incentives70
- Confidence60
Intismeran autogene met both primary endpoints in a 1,137-patient melanoma trial. Every dose is built from one tumour's sequence, which turns approval into a question about process, not product.
Perspective Coverage
3 publishers
- Builder
- Builder 38%
- Operator
- Operator 42%
- Investor
- Investor 20%
Reality
- Evidence40
- Adoption5
- Hype gap+40
- Incentives75
- Confidence55
The companies say intismeran plus Keytruda slowed melanoma's return after surgery in the first randomized Phase 3 test of neoantigen vaccines. No detailed data has been released.
Perspective Coverage
4 publishers
- Builder
- Builder 39%
- Operator
- Operator 36%
- Investor
- Investor 25%
Reality
- Evidence40
- Adoption3
- Hype gap+40
- Incentives70
- Confidence55
Kiwoom's S&P 500 Momentum ETF replaced 54 of its 99 holdings in one scheduled rebalance, putting Apple on top at 9.23%, dropping Nvidia and Broadcom, and raising Intel and AMD to 4.89% each.
Reality
- Evidence55
- Adoption
- Insufficient
- Hype gap+18
- Incentives72
- Confidence52
Hana Asset Management's medical AI fund led every ETF listed in South Korea last week, helped by a Morgan Stanley estimate that Medicare coverage could add $330m to $400m of annual revenue at its largest holding.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+40
- Incentives75
- Confidence45
The Aug. 10 order also cuts the routine childhood list from 18 vaccines to 11 on the argument that the United States is out of step with Europe, and the pediatricians who have read it say no new safety or efficacy data came with it.
Reality
- Evidence66
- Adoption25
- Hype gap+45
- Incentives55
- Confidence58
Revolution Medicines' daraxonrasib nearly doubled median overall survival in previously treated patients. Investors sat still anyway, because the unresolved variable is now what payers will absorb.
Reality
- Evidence70
- Adoption34
- Hype gap+16
- Incentives72
- Confidence61
Intismeran autogene would arrive with a selection procedure where other drugs have a fixed molecule, and the outside expert STAT asked could not say what the software weighs. That makes the ranking code the hard part of any review.
Reality
- Evidence34
- Adoption21
- Hype gap+32
- Incentives66
- Confidence41
Eight investors are named on the round and no valuation was disclosed. The only outside corroboration of Faro's data model covers how it writes protocols, not what agents do with them.
Reality
- Evidence44
- Adoption31
- Hype gap+28
- Incentives72
- Confidence48
MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.
Reality
- Evidence61
- Adoption58
- Hype gap+12
- Incentives74
- Confidence63
Stanford's April 2026 tests put debate ahead of rival multi-agent designs, and behind a solo agent at matched compute. The comparison a framework vendor quotes is the first one.
Reality
- Evidence30
- Adoption16
- Hype gap
- Insufficient
- Incentives
- Insufficient
- Confidence32
The global Ervebo stockpile released doses for an outbreak the shot was not licensed against. Most of them will be given outside the trial that could tell anyone whether it works.
Reality
- Evidence52
- Adoption58
- Hype gap+14
- Incentives38
- Confidence45
Moderna shares rose more than 100% after the melanoma Phase 3 hit, and a co-founder's net worth went from $730 million to $1.7 billion. The wealth number is a risk gauge, not a story.
Reality
- Evidence30
- Adoption
- Insufficient
- Hype gap+42
- Incentives68
- Confidence40
ClickHouse has acquired Langfuse, folding the leading open-source LLM observability project into the database it already ran on. Teams that standardized on it inherit a lock-in decision.
Publishers:clickhouse.com
Reality
- Evidence30
- Adoption62
- Hype gap+28
- Incentives90
- Confidence42
A record long-bond yield in the US and decade-high yields in Germany and France are the week's real story. Mortgages moved first; AI capex plans are next in line for scrutiny.
Reality
- Evidence42
- Adoption24
- Hype gap+22
- Incentives58
- Confidence40